Product
BTKi
1 clinical trial
1 drug
7 indications
Indication
Relapsed Non-Hodgkin LymphomaIndication
Chronic Lymphocytic LeukemiaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Richter syndromeIndication
MYC AmplificationIndication
MYC OverexpressionIndication
MYC TranslocationDrug
BTKiClinical trial
An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter SyndromeStatus: Terminated, Estimated PCD: 2023-05-26